Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
0.75
USD
-1.48%
-23.76%
-63.24%
Presenter SpeechCorinne Jenkins (Analysts)Good morning, and thank you, everyone, for joining u...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $1.74M, vs. Street Est of $2.85M
May. 09
MT
Transcript : Gritstone bio, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09
Gritstone bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 09
CI
Gritstone Bio, Inc. Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA Vaccine at ESCMID Global 2024
Apr. 30
CI
Gritstone Bio, Inc. Announces Board Changes
Apr. 29
CI
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform
Apr. 15
CI
Top Midday Decliners
Apr. 02
MT
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants
Apr. 02
MT
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall
Apr. 01
MT
Gritstone Bio Starts Public Offering; Shares Drop After-Hours
Apr. 01
MT
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite
Apr. 01
CI
Earnings Flash (GRTS) GRITSTONE BIO Posts Q4 Revenue $16.3M
Mar. 05
MT
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 05
CI
Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial
Feb. 12
CI
Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from NASDAQ Biotechnology Index
Dec. 15
CI
B. Riley Adjusts Gritstone bio's Price Target to $6 From $8, Keeps Buy Rating
Dec. 07
MT
Transcript : Gritstone bio, Inc. Presents at First Annual Goldman Sachs Catalyst Clinic, Dec-05-2023 11:00 AM
Dec. 05
Earnings Flash (GRTS) GRITSTONE BIO Posts Q3 Revenue $1.6M
Nov. 08
MT
Gritstone bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 08
CI
Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna Vaccine Candidates Against Covid-19 (Part of the Company?s Coral Program) at IDWeek 2023
23-10-11
CI
Gritstone bio Offers Stock Options to Three New Employees
23-10-10
MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket
23-09-28
MT
Piper Sandler Lifts Price Target on Gritstone bio to $7 From $6, Keeps Overweight Rating
23-09-28
MT
Gritstone Bio Gets Contract For Comparative COVID-19 Trial; Shares Jump After-Hours
23-09-27
MT
Gritstone Bio, Inc. Receives BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19
23-09-27
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
More about the company
Last Close Price
0.75
USD
Average target price
4.333
USD
Spread / Average Target
+477.78%
Consensus
1st Jan change
Capi.
-63.24% 81.43M +0.10% 91.42B +2.76% 41.08B -9.06% 34.26B +55.13% 25.27B -16.61% 15.27B -9.14% 12.81B -12.11% 11.6B -43.61% 11.42B +8.01% 9.16B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
#252525**/registration/member/**Blanc**1**7**To continue browsing, please register!**#ffffff50**14px**#33d251**